Organon & (OGN) Stock Price

Organon & Price

NYSE·CLOSED
13.79
​
Market closed

Revenue at Organon & has contracted by 6.3% per year over the past 8 years to 6.22 B USD. Earnings per share have declined at 24.9% per year over the last 8 years. Organon &'s net margin stands at 3.0%, down from 21.4% several years earlier. Organon & currently offers a dividend yield of about 2.47%. The payout ratio is around 47% of earnings. Analysts set a median price target of 12.00 USD, implying 13.0% below the current price. Of 13 analysts, 0 rate the stock a buy — an overall Sell consensus.

Organon & stock price

Access this data via the Eulerpool API

Organon & business model & stock analysis

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company is headquartered in Jersey City, New Jersey and currently employs 10,000 full-time employees. The company went IPO on 2021-05-14. The firm is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands (Organon Products). Organon has a portfolio of contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing, Follistim AQ, and Elonva. The Company’s Biosimilars portfolio spans immunology and oncology treatments. The company also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. The firm sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The company operates its manufacturing facilities in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.

Frequently asked questions about Organon &

Analysts currently set an average price target of 11.33 USD for the Organon & stock (median: 12.00 USD), implying -17.8 % versus the latest price. The consensus is based on 13 analyst ratings.

13 analysts currently rate the Organon & stock: 0 recommend buying, 7 holding and 6 selling. For 2026, analysts expect Organon & to generate revenue of 6.14 B USD and earnings per share of 3.35 USD.

Converted at the current exchange rate, the Organon & share trades at 12.31 EUR (13.79 USD).

The Organon & share (OGN) is listed on 7 stock exchanges, including: NYSE (OGN), London (0A9W.L), XETRA (7XP.DE), Frankfurt (7XP.F), München (7XP.MU), Düsseldorf (7XP.DU).

The expected revenue of Organon & is 6.14 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Organon & is 870.93 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Organon & is currently 4.12. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Organon & stock.

The price-to-sales ratio (P/S) of Organon & is currently 0.58. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Organon & stock.

The Eulerpool Quality Score for Organon & is 1/10.

The ISIN of Organon & is US68622V1061. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Organon & is A3CPKP. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Organon & is OGN. The ticker symbol is used to trade Organon & shares on the stock exchange.

Fair ValueTerminal
11.45 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
621,600.00 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website organon.com
Currency
USD
Initial public offering
May 14, 2021
ISIN
US68622V1061
Cusip
68622V106
Market capitalization
3.59 B USDMid Cap
52-Week Range
PEG
6.22
P/E ratio
P/Ee 2026
4.12
P/Ee 2027
3.80
P/Ee 2028
3.44
P/Ee 2029
3.63
P/Ee 2030
3.54
P/S
P/Se
0.58
EV/EBIT
12.59
P/B Ratio
4.77
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
1.98 %
Dividend
Dividend yield
2.47 %
Est. Dividend Yield
0.58 %
Payout Ratio
47.30 %
Dividend growth Ø5Y
—
Dividend payments per year
4
Dividend paid since
5 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
30.00 %
Last updated Oct 8, 2026, 10:24 PM

Organon & Peer Group

Organon & Ticker

DÜSSELDORF · 7XP.DUFRANKFURT · 7XP.FLONDON · 0A9W.LMILAN · 1OGN.MIMUNICH · 7XP.MUNEW YORK · OGNXETRA · 7XP.DE

Organon & FIGI

OGN:US · BBG00ZQRGW24OGN:UA · BBG00ZQRJTX4OGN:UC · BBG00ZQRJTY3OGN:UN · BBG00ZQRJV05OGN:UP · BBG00ZQRJV14OGN:UB · BBG00ZQRJV41OGN:UT · BBG00ZQRJV50OGN:UM · BBG00ZQRJV69OGN:UX · BBG00ZQRJV78OGN:UD · BBG00ZQRJVD1OGN:UF · BBG00ZQRJVH7OGN:VY · BBG00ZQRJVJ5

All fundamentals and in-depth analysis of Organon &

Our stock analysis for Organon & stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Organon &. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.